RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) , citing it as a commercial-stage biotech pioneering the rare genetic obesity market.Analyst Lisa Walter wrote on Wednesday that Rhythm Pharmaceuticals’ Phase 3 success in hypothalamic obesity (HO) in 2025 led to a stock rally and a ~$3.5 billion market-cap gain.Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region that regulates appetite and metabolism.Rare Obesity Opportun ...